Novartis' Gorsky to return to J&J

Well, we didn't have to watch Alex Gorsky (photo) for long. According to the Wall Street Journal, when Novartis said that the U.S. pharma CEO was leaving, they left out the part about his returning to alma mater Johnson & Johnson. Gorsky will be chairman of Ethicon, a J&J unit that makes surgical equipment and sutures. Gorsky left J&J to join Novartis in 2004.

Novartis also told the WSJ that Gorsky's exit had nothing to do with any of the changes new worldwide pharma chief Joe Jiminez is making at the company.

- check out the story in the Wall Street Journal

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.